Prediction of Drug-Like Molecular Properties

[1]  Yi Lu,et al.  Resonance Raman spectroscopy of cytochrome c peroxidase variants that mimic manganese peroxidase , 2003, JBIC Journal of Biological Inorganic Chemistry.

[2]  Gabriele Cruciani,et al.  Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. , 2003, Journal of medicinal chemistry.

[3]  J. Halpert,et al.  A Rational Approach to Re-engineer Cytochrome P450 2B1 Regioselectivity Based on the Crystal Structure of Cytochrome P450 2C5* , 2003, The Journal of Biological Chemistry.

[4]  R. Sheridan,et al.  A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. , 2003, Journal of medicinal chemistry.

[5]  Sean Ekins,et al.  In vitro and pharmacophore insights into CYP3A enzymes. , 2003, Trends in pharmacological sciences.

[6]  C. Gartner.  Photoaffinity ligands in the study of cytochrome p450 active site structure. , 2003, Current medicinal chemistry.

[7]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[8]  D. Lewis,et al.  Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: investigation of enzyme-substrate and enzyme-inhibitor interactions. , 2003, Toxicology in vitro : an international journal published in association with BIBRA.

[9]  Min Zhang,et al.  Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. , 2003, Journal of medicinal chemistry.

[10]  Nico P E Vermeulen,et al.  Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. , 2003, Journal of medicinal chemistry.

[11]  D. Garfinkel.  Studies on pig liver microsomes I. Enzymic and pigment composition of different microsomal fractions. , 1958, Archives of biochemistry and biophysics.

[12]  D. Lewis.  Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. , 2003, Archives of biochemistry and biophysics.

[13]  T. Darden,et al.  Explicit water near the catalytic I helix Thr in the predicted solution structure of CYP2A4. , 2003, Biophysical journal.

[14]  Asuka Nanbo,et al.  Mechanistic Study on N‐Demethylation Catalyzed with P450 by Quantitative Structure Activity Relationship using Electronic Properties of 4‐Substituted N,N‐Dimethylaniline , 2002 .

[15]  Danielson Pb,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002 .

[16]  Stewart B Kirton,et al.  Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6 , 2002, Proteins.

[17]  C. Masimirembwa,et al.  The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. , 2002, Biochemical pharmacology.

[18]  Christine M. Bathelt,et al.  Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking , 2002, Journal of molecular modeling.

[19]  Sean Ekins,et al.  Three‐Dimensional Quantitative Structure Activity Relationship for Cyp2d6 Substrates , 2002 .

[20]  G. Szklarz,et al.  Molecular Modeling of Cytochrome P450 1A1: Enzyme-Substrate Interactions and Substrate Binding Affinities , 2002, Journal of biomolecular structure & dynamics.

[21]  D. F. V. Lewis,et al.  Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor α (hERα) LBD: quantitative structure–activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  Vladlen S. Skvortsov,et al.  [Computer model of 3D structure of cytochrome P450 2B4]. , 2002, Voprosy meditsinskoi khimii.

[23]  Ramon Carbó-Dorca,et al.  Molecular Quantum Similarity-Based QSARs for Binding Affinities of Several Steroid Sets , 2002, J. Chem. Inf. Comput. Sci..

[24]  Serge Léger,et al.  Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. , 2002, Biochemistry.

[25]  Gisbert Schneider,et al.  A fast virtual screening filter for cytochrome P450 3A4 inhibition liability of compound libraries , 2002 .

[26]  B G Lake,et al.  Quantitative structure--activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families. , 2002, Toxicology.

[27]  Ismael Zamora,et al.  Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors , 2002, J. Comput. Aided Mol. Des..

[28]  H. Waterbeemd,et al.  Can the Internet help to meet the challenges in ADME and e-ADME? , 2002 .

[29]  Barry C Jones,et al.  Development of a combined protein and pharmacophore model for cytochrome P450 2C9. , 2002, Journal of medicinal chemistry.

[30]  Stewart B Kirton,et al.  Comparative modelling of cytochromes P450. , 2002, Advanced drug delivery reviews.

[31]  Anthony Long,et al.  Computer systems for the prediction of xenobiotic metabolism. , 2002, Advanced drug delivery reviews.

[32]  György M. Keserü,et al.  METAPRINT: A Metabolic Fingerprint. Application to Cassette Design for High-Throughput ADME Screening , 2002, J. Chem. Inf. Comput. Sci..

[33]  György M Keseru,et al.  A neural network based virtual screening of cytochrome P450 3A4 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[34]  Tommy B Andersson,et al.  Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. , 2002, The Journal of pharmacology and experimental therapeutics.

[35]  A. Cavalli,et al.  Looking for selectivity among cytochrome P450s inhibitors. , 2002, Journal of medicinal chemistry.

[36]  Kenneth M. Merz,et al.  Computation of the physio‐chemical properties and data mining of large molecular collections , 2002, J. Comput. Chem..

[37]  D. Lewis,et al.  Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. , 2002, Toxicology.

[38]  D. Lewis,et al.  Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  David F. V. Lewis,et al.  Structure–activity relationship for human cytochrome P450 substrates and inhibitors , 2002, Drug metabolism reviews.

[40]  I. Pajeva,et al.  Quantitative structure-activity relationship (QSAR) and three-dimensional QSAR analysis of a series of xanthates as inhibitors and inactivators of cytochrome P450 2B1 , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[41]  David F. V. Lewis,et al.  Molecular modeling of human cytochrome P450–substrate interactions , 2002, Drug metabolism reviews.

[42]  D. Lewis,et al.  Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[43]  Tudor I. Oprea,et al.  Virtual Screening in Lead Discovery: A Viewpoint† , 2002, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.

[44]  R. Clark,et al.  Consensus scoring for ligand/protein interactions. , 2002, Journal of molecular graphics & modelling.

[45]  D. Nelson,et al.  Mining databases for cytochrome P450 genes. , 2002, Methods in enzymology.

[46]  Ismael Zamora,et al.  Combining pharmacophore and protein modeling to predict CYP450 inhibitors and substrates. , 2002, Methods in enzymology.

[47]  J. Halpert,et al.  Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[48]  T. Andersson,et al.  Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. , 2001, Journal of medicinal chemistry.

[49]  M. Machius,et al.  Pivotal role of water in the mechanism of P450BM-3. , 2001, Biochemistry.

[50]  J. Halpert,et al.  Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. , 2001, Biochemistry.

[51]  A. Hofacre,et al.  Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. , 2001, Journal of molecular biology.

[52]  György M. Keserü,et al.  A virtual high throughput screen for high affinity cytochrome P450cam substrates. Implications for in silico prediction of drug metabolism , 2001, J. Comput. Aided Mol. Des..

[53]  Stephen Ploch,et al.  Induction of hepatic aromatase by p,p′-DDE in adult male rats , 2001, Molecular and Cellular Endocrinology.

[54]  D. F. Lewis,et al.  Application of process chemistry and SAR modelling to the evaluation of health findings of lower olefins. , 2001, Chemico-biological interactions.

[55]  J. Halpert,et al.  Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. , 2001, Current drug metabolism.

[56]  M. Waterman,et al.  Evolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact points , 2001, The EMBO journal.

[57]  P A Kollman,et al.  Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. , 2001, Journal of medicinal chemistry.

[58]  A. Lisitsa,et al.  Inventory of the cytochrome P450 superfamily , 2001 .

[59]  G. Tucker,et al.  Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. , 2001, The Biochemical journal.

[60]  C. Masimirembwa,et al.  Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. , 2001, Molecular pharmacology.

[61]  T. Poulos,et al.  Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  D. Lewis,et al.  COMPACT: a structural approach to the modelling of cytochromes P450 and their interactions with xenobiotics , 2001 .

[63]  Antti Poso,et al.  A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors , 2001, J. Comput. Aided Mol. Des..

[64]  J. Halpert,et al.  Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles. , 2001, Molecular pharmacology.

[65]  E Baston,et al.  Synthesis, evaluation and QSAR studies of highly potent aromatase inhibitors of the piperidinedione type. , 2001, Anti-cancer drug design.

[66]  A. Cavalli,et al.  A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. , 2001, Journal of medicinal chemistry.

[67]  Maurice Dickins,et al.  Quantitative Structure-Activity Relationships (QSARs) Within Series of Inhibitors for Mammalian Cytochromes P450 (CYPs) , 2001, Journal of enzyme inhibition.

[68]  M. Dickins,et al.  Quantitative Structure-Activity Relationships (QSARs) Within Substrates of Human Cytochromes P450 Involved in Drug Metabolism , 2001, Drug metabolism and drug interactions.

[69]  S W Allen,et al.  Recent advances in P450 research , 2001, The Pharmacogenomics Journal.

[70]  Nenad Trinajstić,et al.  Predicting Inhibition of Microsomal p-Hydroxylation of Aniline by Aliphatic Alcohols: A QSAR Approach Based on the Weighted Path Numbers , 2001 .

[71]  A. Cavalli,et al.  Linking CoMFA and protein homology models of enzyme-inhibitor interactions: an application to non-steroidal aromatase inhibitors. , 2000, Bioorganic & medicinal chemistry.

[72]  S. D. Turner,et al.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[73]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[74]  D. Lewis,et al.  On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. , 2000, Biochemical pharmacology.

[75]  S. Ekins,et al.  Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.

[76]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[77]  Jeffrey P. Jones,et al.  A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. , 2000, Journal of medicinal chemistry.

[78]  Wannian Zhang,et al.  A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. , 2000, Journal of medicinal chemistry.

[79]  Young-Sang Choi,et al.  Quantitative Structure-Activity Relationships (QSAR) Study of Flavonoid Derivatives for Inhibition of Cytochrome P450 1A2 , 2000 .

[80]  Ferran Sanz,et al.  3D-QSAR methods on the basis of ligand–receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands , 2000, J. Comput. Aided Mol. Des..

[81]  C Masimirembwa,et al.  Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. , 2000, Biochemical and biophysical research communications.

[82]  G. Miller,et al.  Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.

[83]  D. Lewis,et al.  Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. , 2000, Toxicology.

[84]  A. Y. Lu,et al.  Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[85]  Gianpaolo Bravi,et al.  Application of MS‐WHIM Descriptors: 1. Introduction of New Molecular Surface Properties and 2. Prediction of Binding Affinity Data , 2000 .

[86]  D E McRee,et al.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.

[87]  Francesca Fanelli,et al.  Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4 , 2000, J. Comput. Aided Mol. Des..

[88]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[89]  Jeffrey P. Jones,et al.  Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. , 1999, Archives of biochemistry and biophysics.

[90]  J B Houston,et al.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.

[91]  G. Loew,et al.  Homology modeling and substrate binding study of human CYP2C9 enzyme , 1999, Proteins.

[92]  G H Loew,et al.  Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes , 1999, Proteins.

[93]  H. Strobel,et al.  Heterobifunctional photoaffinity probes for cytochrome P450 2B. , 1999, Archives of biochemistry and biophysics.

[94]  D T Jones,et al.  Protein secondary structure prediction based on position-specific scoring matrices. , 1999, Journal of molecular biology.

[95]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[96]  P. Ortiz de Montellano,et al.  Deuterium magic angle spinning studies of substrates bound to cytochrome P450. , 1999, Biochemistry.

[97]  D. Lewis.  Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity. , 1999, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[98]  S. Ekins,et al.  Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.

[99]  J. Venhorst,et al.  Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening. , 1999, Chemical research in toxicology.

[100]  Gilles Klopman,et al.  META 4. Prediction of the metabolism of polycyclic aromatic hydrocarbons , 1999 .

[101]  A. Alex,et al.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[102]  M H Tarbit,et al.  Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. , 1999, Toxicology.

[103]  Robert L. Haining,et al.  Enzymatic Determinants of the Substrate Specificity of CYP2C9: Role of B‘−C Loop Residues in Providing the π-Stacking Anchor Site for Warfarin Binding† , 1999 .

[104]  Vithal M. Kulkarni,et al.  Three-Dimensional Quantitative Structure-Activity Relationship (QSAR) and Receptor Mapping of Cytochrome P-45014DM Inhibiting Azole Antifungal Agents1 , 1999, J. Chem. Inf. Comput. Sci..

[105]  M H Tarbit,et al.  Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[106]  D. Lewis,et al.  Molecular modelling of CYP4A subfamily members based on sequence homology with CYP102. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[107]  M H Tarbit,et al.  Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives. , 1999, Journal of enzyme inhibition.

[108]  P N Judson,et al.  Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.

[109]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.

[110]  J. Halpert,et al.  Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[111]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[112]  John P. Overington,et al.  HOMSTRAD: A database of protein structure alignments for homologous families , 1998, Protein science : a publication of the Protein Society.

[113]  M. Pincus,et al.  Inhibition of human cytochrome P450 1A2 by flavones: A molecular modeling study , 1998, Journal of protein chemistry.

[114]  J. Peterson,et al.  A close family resemblance: the importance of structure in understanding cytochromes P450. , 1998, Structure.

[115]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[116]  J. Halpert,et al.  Probing the active site of cytochrome P450 2B1: metabolism of 7-alkoxycoumarins by the wild type and five site-directed mutants. , 1998, Biochemistry.

[117]  C. Yoon,et al.  Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. , 1998, Biochemical pharmacology.

[118]  A. Cavalli,et al.  Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes. , 1998, Bioorganic & medicinal chemistry.

[119]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[120]  M Pastor,et al.  Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. , 1998, Journal of medicinal chemistry.

[121]  M. Pincus,et al.  Molecular Modeling of Cytochrome P450 2B1: Mode of Membrane Insertion and Substrate Specificity , 1998, Journal of protein chemistry.

[122]  D. Lewis,et al.  Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. , 1998, Toxicology.

[123]  D. Parke,et al.  Further evaluation of COMPACT, the molecular orbital approach for the prospective safety evaluation of chemicals. , 1998, Mutation research.

[124]  Tirso Pons,et al.  Homology modeling, model and software evaluation: three related resources , 1998, Bioinform..

[125]  T Ishizaki,et al.  Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. , 2003, British journal of clinical pharmacology.

[126]  J. Halpert,et al.  Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. , 1997, Life sciences.

[127]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an NMR study. , 1997, Biochemistry.

[128]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[129]  Ferran Sanz,et al.  Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ , 1997, J. Comput. Aided Mol. Des..

[130]  Substrate Docking Algorithms and Prediction of the Substrate Specificity of Cytochrome P450cam and Its L244A Mutant , 1997 .

[131]  M Pastor,et al.  Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. , 1997, Journal of medicinal chemistry.

[132]  Grazyna D. Szklarz,et al.  Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..

[133]  W U Primrose,et al.  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. , 1997, Biochemistry.

[134]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[135]  M H Tarbit,et al.  Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[136]  M Pastor,et al.  Reliability of comparative molecular field analysis models: effects of data scaling and variable selection using a set of human synovial fluid phospholipase A2 inhibitors. , 1997, Journal of medicinal chemistry.

[137]  Gilles Klopman,et al.  META, 3. A Genetic Algorithm for Metabolic Transform Priorities Optimization , 1997, J. Chem. Inf. Comput. Sci..

[138]  C. S. Yang,et al.  A hypothetical model for the active site of human cytochrome P4502E1. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[139]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[140]  John Fox,et al.  Representation of Chemical Structures in Knowledge-Based Systems: The StAR System , 1997, J. Chem. Inf. Comput. Sci..

[141]  N. Vermeulen,et al.  A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.

[142]  Roberto Todeschini,et al.  MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids , 1997, J. Comput. Aided Mol. Des..

[143]  J. G. Snijders,et al.  Extension of a predictive substrate model for human cytochrome P4502D6. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[144]  D. Mansuy,et al.  Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.

[145]  G. Veith,et al.  A QSAR evaluation of Ah receptor binding of halogenated aromatic xenobiotics. , 1996, Environmental health perspectives.

[146]  S. Wodak,et al.  Deviations from standard atomic volumes as a quality measure for protein crystal structures. , 1996, Journal of molecular biology.

[147]  Grazyna D. Szklarz,et al.  Secobarbital-mediated Inactivation of Cytochrome P450 2B1 and Its Active Site Mutants , 1996, The Journal of Biological Chemistry.

[148]  N. Vermeulen,et al.  A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.

[149]  G. Loew,et al.  Refinement of 3D models of horseradish peroxidase isoenzyme C: Predictions of 2D NMR assignments and substrate binding sites , 1996, Proteins.

[150]  R J Fletterick,et al.  Structure-based design of parasitic protease inhibitors. , 1996, Bioorganic & medicinal chemistry.

[151]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[152]  John Fox,et al.  Using New Reasoning Technology in Chemical Information Systems , 1996, J. Chem. Inf. Comput. Sci..

[153]  Tudor I. Oprea,et al.  Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors , 1996, J. Comput. Aided Mol. Des..

[154]  W U Primrose,et al.  A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. , 1996, Biochemistry.

[155]  L. Benet,et al.  The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics , 1996, Clinical pharmacology and therapy.

[156]  T. Wobbes,et al.  Comparative MO-QSAR studies in various species including man. , 1996, Chemico-biological interactions.

[157]  P. Maurel,et al.  Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. , 1996, Biochemical pharmacology.

[158]  D A Smith,et al.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[159]  C. Waller,et al.  Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[160]  Jeffrey P. Jones,et al.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[161]  M H Tarbit,et al.  Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[162]  Chris Sander,et al.  The FSSP database: fold classification based on structure-structure alignment of proteins , 1996, Nucleic Acids Res..

[163]  Michael J. E. Sternberg,et al.  Evidence That Aspartic Acid 301 Is a Critical Substrate-Contact Residue in the Active Site of Cytochrome P450 2D6 (*) , 1995, The Journal of Biological Chemistry.

[164]  Gareth Jones,et al.  A genetic algorithm for flexible molecular overlay and pharmacophore elucidation , 1995, J. Comput. Aided Mol. Des..

[165]  D. Lewis,et al.  Molecular orbital-generated QSARs in a homologous series of alkoxyresorufins and studies of their interactive docking with P450s. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[166]  J. Halpert,et al.  Site-directed mutagenesis as a tool for molecular modeling of cytochrome P450 2B1. , 1995, Biochemistry.

[167]  A. Wood,et al.  Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test. , 1995, British journal of clinical pharmacology.

[168]  C. Ioannides,et al.  A quantitative structure-activity relationship study on a series of 10 para-substituted toluenes binding to cytochrome P4502B4 (CYP2B4), and their hydroxylation rates. , 1995, Biochemical pharmacology.

[169]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[170]  J. Vervoort,et al.  1H NMR T 1 relaxation rate study on substrate orientation of fluoromethylanilines in the active sites of microsomal and purified cytochromes P450 1A1 and 2B1 , 1995, FEBS letters.

[171]  R. Wade,et al.  Prediction of drug binding affinities by comparative binding energy analysis , 1995 .

[172]  D. Lewis,et al.  Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[173]  D F Lewis,et al.  A retrospective evaluation of COMPACT predictions of the outcome of NTP rodent carcinogenicity testing. , 1995, Environmental health perspectives.

[174]  A. I. Archakov,et al.  Cytochrome P450 database for prediction of drugs' fate in living systems , 1995 .

[175]  J Deisenhofer,et al.  Structure and function of cytochromes P450: a comparative analysis of three crystal structures. , 1995, Structure.

[176]  J. Halpert,et al.  Structural basis of selective cytochrome P450 inhibition. , 1995, Annual review of pharmacology and toxicology.

[177]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[178]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[179]  Gilles Klopman,et al.  META. 2. A Dictionary Model of Mammalian Xenobiotic Metabolism , 1994, J. Chem. Inf. Comput. Sci..

[180]  R. Ornstein,et al.  Application of 3-dimensional homology modeling of cytochrome P450 2B1 for interpretation of site-directed mutagenesis results. , 1994, Journal of biomolecular structure & dynamics.

[181]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[182]  D. Lewis,et al.  Interaction of a series of nitriles with the alcohol-inducible isoform of P450: computer analysis of structure-activity relationships. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[183]  J. Coggins,et al.  Resonance Raman spectroscopic studies on intact cytochrome P450 BM3. , 1994, Biochemical Society transactions.

[184]  Burkhard Rost,et al.  PHD - an automatic mail server for protein secondary structure prediction , 1994, Comput. Appl. Biosci..

[185]  Ferran Sanz,et al.  THEORETICAL STUDY ON THE METABOLISM OF CAFFEINE BY CYTOCHROME P-450 1A2 AND ITS INHIBITION , 1994 .

[186]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[187]  Andrew Howard,et al.  Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam , 1993 .

[188]  T. Yeates,et al.  Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.

[189]  J Deisenhofer,et al.  Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.

[190]  D S Moss,et al.  Main-chain bond lengths and bond angles in protein structures. , 1993, Journal of molecular biology.

[191]  Nico P. E. Vermeulen,et al.  A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building , 1993, J. Comput. Aided Mol. Des..

[192]  R. Raag,et al.  Inhibitor-induced conformational change in cytochrome P-450CAM. , 1993, Biochemistry.

[193]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[194]  F. Sanz,et al.  Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. , 1993, Molecular pharmacology.

[195]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[196]  F. Guengerich,et al.  Modification of cytochrome P450 1A2 enzymes by the mechanism-based inactivator 2-ethynylnaphthalene and the photoaffinity label 4-azidobiphenyl. , 1992, Biochemistry.

[197]  C. Waller,et al.  Comparative molecular field analysis of polyhalogenated dibenzo-p-dioxins, dibenzofurans, and biphenyls. , 1992, Journal of medicinal chemistry.

[198]  I. Kuntz.  Structure-Based Strategies for Drug Design and Discovery , 1992, Science.

[199]  David F. V. Lewis,et al.  The sequence homologies of cytochromes P-450 and active-site geometries , 1992, J. Comput. Aided Mol. Des..

[200]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[201]  S A van Acker,et al.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.

[202]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[203]  Glen Eugene Kellogg,et al.  HINT: A new method of empirical hydrophobic field calculation for CoMFA , 1991, J. Comput. Aided Mol. Des..

[204]  M J Sternberg,et al.  A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. , 1991, Carcinogenesis.

[205]  T. Kitagawa,et al.  Unusual CO bonding geometry in abnormal subunits of hemoglobin M Boston and hemoglobin M Saskatoon. , 1991, Biochemistry.

[206]  R. Raag,et al.  Crystal structures of cytochrome P-450CAM complexed with camphane, thiocamphor, and adamantane: factors controlling P-450 substrate hydroxylation. , 1991, Biochemistry.

[207]  W. Pearson.  Rapid and sensitive sequence comparison with FASTP and FASTA. , 1990, Methods in enzymology.

[208]  R. Raag,et al.  The structural basis for substrate-induced changes in redox potential and spin equilibrium in cytochrome P-450CAM. , 1991, Biochemistry.

[209]  György G. Ferenczy,et al.  The active site of cytochrome P-450 nifedipine oxidase: a model-building study. , 1989, Journal of molecular graphics.

[210]  D. Nelson,et al.  Secondary structure prediction of 52 membrane-bound cytochromes P450 shows a strong structural similarity to P450cam. , 1989, Biochemistry.

[211]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[212]  F. Darvas,et al.  Predicting metabolic pathways by logic programming , 1988 .

[213]  D. Nelson,et al.  On the membrane topology of vertebrate cytochrome P-450 proteins. , 1988, The Journal of biological chemistry.

[214]  Subhash C. Basak.  Binding of barbiturates to cytochrome P450: A QSAR study using log P and topological indices , 1988 .

[215]  C. Ioannides,et al.  The cytochromes P-448--a unique family of enzymes involved in chemical toxicity and carcinogenesis. , 1987, Biochemical pharmacology.

[216]  T. Poulos,et al.  High-resolution crystal structure of cytochrome P450cam. , 1987, Journal of molecular biology.

[217]  Christian Mailhiot,et al.  Electronic structure of (001)- and (111)-growth-axis semiconductor superlattices , 1987 .

[218]  I. Kuntz,et al.  Docking flexible ligands to macromolecular receptors by molecular shape. , 1986, Journal of medicinal chemistry.

[219]  D. Lewis,et al.  Molecular dimensions of the substrate binding site of cytochrome P-448. , 1986, Biochemical pharmacology.

[220]  C Skoda,et al.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[221]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[222]  F. Guengerich,et al.  Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. , 1985, Cancer research.

[223]  K. Kaiser,et al.  QSAR in Environmental Toxicology - II , 1984 .

[224]  J. Ozols,et al.  The complete amino acid sequence of rabbit phenobarbital-induced liver microsomal cytochrome P-450. , 1983, The Journal of biological chemistry.

[225]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[226]  Bernard Testa,et al.  Drug Metabolism: Chemical and Biochemical Aspects , 1976 .

[227]  J N Smith,et al.  The comparative metabolism of xenobiotics. , 1968, Advances in comparative physiology and biochemistry.

[228]  M. Klingenberg.  Pigments of rat liver microsomes. , 1958, Archives of biochemistry and biophysics.

[229]  J. Cooper,et al.  Detoxication of drugs and other foreign compounds by liver microsomes. , 1955, Science.